On top of high-quality, day-to-day performance in areas such as prosecution, litigation and licensing, there are three essential elements an in-house function requires to be part of the elite Read more
The World Intellectual Property Organization rolled out its new timestamping solution in May and while it has a lot going for it, there are downsides too Read more
After a bruising WIPO director-general election process, Singaporean nominee’s first priority should be to build bridges between the US and China Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Our annual snapshot of the industry keeps the EPO at the top of the big five but suggests that the shine may have come off Andrei Iancu’s reign Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Our annual snapshot of the industry keeps the EPO at the top of the big five but suggests that the shine may have come off Andrei Iancu’s reign Read more
Our annual snapshot of the industry keeps the EPO at the top of the big five but suggests that the shine may have come off Andrei Iancu’s reign Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Our annual snapshot of the industry keeps the EPO at the top of the big five but suggests that the shine may have come off Andrei Iancu’s reign Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Our annual snapshot of the industry keeps the EPO at the top of the big five but suggests that the shine may have come off Andrei Iancu’s reign Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
A covid-19 vaccine could be produced by anyone, but only a few major players had been actively strengthening and building their portfolios before the pandemic struck Read more
The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
A covid-19 vaccine could be produced by anyone, but only a few major players had been actively strengthening and building their portfolios before the pandemic struck Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
@IAM_magazine RT @IAM_magazine: The IAM Sunday Supplement is now out, including: IV and RPX mega deal; Huawei secures BlackBerry IP; China’s patent attor… Read more
17Jan2021
@IAM_magazine RT @safiranand: My interview to @IAM_magazine on winning strategies for IP and it’s monetisation. IAM is amongst the best monetisation reso… Read more
